Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8(+) T cell immune response and antitumor effects in a preclinical cervical cancer model

BACKGROUND: Bortezomib, a proteasome inhibitor and suberoylanilide hydroxamic acid (SAHA, also known as Vorinostat), a histone deacetylase inhibitor, have been recognized as potent chemotherapeutic drugs. Bortezomib and SAHA are FDA-approved for the treatment of cutaneous T cell lymphoma and multipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zhuomin, Peng, Shiwen, Knoff, Jayne, Lee, Sung Yong, Yang, Benjamin, Wu, Tzyy-Choou, Hung, Chien-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298946/
https://www.ncbi.nlm.nih.gov/pubmed/25591912
http://dx.doi.org/10.1186/s12929-014-0111-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298946/
https://www.ncbi.nlm.nih.gov/pubmed/25591912
http://dx.doi.org/10.1186/s12929-014-0111-1

Ejemplares similares